Covered Companies

Tapimmune - TPIV

Tapimmune (TPIV)

http://www.tapimmune.com

Coverage: January 21, 2010 - March 21, 2010

Featured: January 21, 2010

Latest Newsletter Editions

Nothing Like a Cool $200 Million (TPIV)

Mon, Feb 1, 2010 @ 03:02 pm

Nothing Like a Cool $200 Million You might wonder who's got the cool $200 million, and what it has to do with today's edition of the OTC Journal. Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I said some positive developments would start to roll their way, and today's post close news...

Two Beat Downs; Stand By

Wed, Jan 27, 2010 @ 09:01 am

Two Beat Downs; Stand By I just wanted to publish a couple of quick notes on two stocks I've been covering and have made comments on recently. First on China Recycling Energy (CREG)- someone is selling the stock fairly ruthlessly with little regard for price. It started two days ago, and the stock is...

Cancer Killer Tapimmune (TPIV) Reincarnated

Thu, Jan 21, 2010 @ 01:01 pm

How The Immune System Fights Disease Our bodies have a miraculous capability. Our Immune System, through a complex network of cells and chemicals, has the ability to identify bad stuff and rapidly recruit an army to attack foreign invaders and kill them. T-Cells are the circus ring masters. The T-Cells...

Latest Blog Entries

Quote Data

Last Trade:	0.30	Bid:	0.3000
Last Size:	10,000	Ask:	0.3300
Trade Time:	4:38pm	Bid x Ask Size:	5000x5000
Change:	-0.0060 (-1.96%)	Day's Range:	0.27 - 0.34
Prev Close:	0.3060	52wk Range:	0.06 - 0.20
Open:	0.3300	P/E (ttm):	N/A
Volume:	208,063	EPS (ttm):	0.00

Business Summary

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

Disclosure

MarketByte LLC has purchased 200,000 shares of Tapimmune with a cost basis of fifteen cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.

Current Position as of 03/05/10:
137,500 Shares

Total Dollars Liquidated as of 03/05/10:
$31,044.28